+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Cyramza"

Bevacizumab Biosimilars Global Market Report 2024 - Product Thumbnail Image

Bevacizumab Biosimilars Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
From
From
Colorectal Cancer KOL Interview - UK - Product Thumbnail Image

Colorectal Cancer KOL Interview - UK

  • Newsletter
  • March 2024
  • 14 Pages
  • United Kingdom
Colorectal Cancer KOL Interview - US, Northeast - Product Thumbnail Image

Colorectal Cancer KOL Interview - US, Northeast

  • Newsletter
  • March 2024
  • 14 Pages
  • United States
Colorectal Cancer Forecast and Market Analysis to 2036 - Product Thumbnail Image

Colorectal Cancer Forecast and Market Analysis to 2036

  • Report
  • September 2018
  • 630 Pages
  • Global
From
Cyramza (ramucirumab; Eli Lilly) Drug Overview 2019 - Product Thumbnail Image

Cyramza (ramucirumab; Eli Lilly) Drug Overview 2019

  • Drug Pipelines
  • September 2019
  • 65 Pages
  • Global
Lorlatinib - Product Thumbnail Image

Lorlatinib

  • Report
  • August 2018
  • 16 Pages
  • Global
From
Disease Analysis: Non-Small Cell Lung Cancer (NSCLC) - Product Thumbnail Image

Disease Analysis: Non-Small Cell Lung Cancer (NSCLC)

  • Report
  • April 2021
  • 191 Pages
  • Global
Cyramza- Drug Insight, 2019 - Product Thumbnail Image

Cyramza- Drug Insight, 2019

  • Report
  • January 2019
  • 35 Pages
  • Global
From
Disease Analysis: Colorectal Cancer - Product Thumbnail Image

Disease Analysis: Colorectal Cancer

  • Report
  • May 2021
  • 88 Pages
  • Global
  • 12 Results (Page 1 of 1)
Loading Indicator

Cyramza (ramucirumab) is a monoclonal antibody drug used to treat certain types of lung cancer. It is used in combination with other drugs to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Cyramza works by blocking the activity of a protein called vascular endothelial growth factor (VEGF), which helps cancer cells grow and spread. Cyramza is approved by the US Food and Drug Administration (FDA) for the treatment of NSCLC in combination with other drugs. The Cyramza market is a rapidly growing segment of the global lung cancer drugs market. It is expected to witness strong growth in the coming years due to the increasing prevalence of lung cancer and the growing demand for effective treatments. The market is also driven by the increasing number of clinical trials and the availability of new drugs. Some of the key players in the Cyramza market include Eli Lilly and Company, Merck & Co., Inc., AstraZeneca, Pfizer Inc., and Bristol-Myers Squibb Company. Show Less Read more